US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.210 +0.030 (+2.54%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
Via ACCESSWIRE
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Advances Copper-Binding Drug for Wilson’s Disease and Age-Related Therapies
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Via ACCESSWIRE
News headline image
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease ↗
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation. 
Via Benzinga
News headline image
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Via ACCESSWIRE
News headline image
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation 
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Via ACCESSWIRE
News headline image
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday? ↗
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases. 
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Breakthrough Preclinical Results in Type 2 Diabetes Treatment
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Via ACCESSWIRE
News headline image
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study 
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Via ACCESSWIRE
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Via ACCESSWIRE
News headline image
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs 
Via News Direct
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Via ACCESSWIRE
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024 ↗
Telomir Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging 
Via News Direct
News headline image
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024 ↗
Telomir Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
News headline image
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket ↗
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >